The agreement would help the U.S. drugmaker take the experimental Ebola vaccine through late-stage clinical trials to licensing and then through pre-qualification by the WHO. GAVI is an international coalition of partners which includes national governments, international organizations such as the United Nations Children’s Fund (UNICEF), the World Health Organization (WHO) and the World Bank; philanthropic institutions, the private sector, represented by the International Federation of Pharmaceutical Manufacturers Associations (IFPMA); and research and public health institutions. Merck’s so-called VSV-ZEBOV live attenuated Ebola Zaire vaccine would become one of the world’s first licensed Ebola shots. It will be possible this way to create a stockpile for future outbreak. The vaccine will be submitted for a license by the end of 2017 but Merck will ensure that 300,000 doses of the vaccine are available from May 2016 to be used in expanded use clinical trials as well as for emergency use as needed.